Slide 1: OraSure Technologies Investor Presentation May 2021
OraSure Technologies Investor presentation MAy 2021 Exhibit 99.3
Slide 2: Forward-Looking Statements Disclaimer
Forward-Looking Statements Disclaimer This presentation contains certain forward-looking statements, including with respect to expected revenues and earnings/loss per share. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause act
Slide 3: Company Snapshot
Company Snapshot 1Cash and cash equivalents, short-term investments, and long-term investments as of March 31, 2020 2 Infectious Disease and Risk Assessment Testing Sampling tools, services and diagnostics to understand what’s in us, on us, and around us. 570 employees $240 million in cash1 on balan
Slide 4: Investment Rationale
Investment Rationale Multiple Near-term COVID-19 Opportunities and Long-term Growth Drivers Well positioned to simplify global COVID-19 testing: Two self-collection devices for molecular testing received EUAs + CE-IVD marks and are in wide use EUA application submitted for COVID-19 rapid antigen tes
Slide 5: Improving Global Access to Accurate Healthcare Information
Improving Global Access to Accurate Healthcare Information Experts in sample collection, preservation and diagnostics Over 20 years of proprietary knowledge in oral fluid testing enables self collection and rapid in-home results Broad, well-established channels of distribution across global public h
Slide 6: Capitalizing on Next-generation Health and Wellness Technologies
Capitalizing on Next-generation Health and Wellness Technologies Innovative sampling tools, services and diagnostics help people understand what’s in us, on us, and around us Unlocking access to accurate essential information that advances global health and well-being Driving access to multiple laye
Slide 7: OraSure Solutions
OraSure Solutions Study design Customization Single-order fulfillment Wet lab & sequencing Analysis Consulting Infectious disease Substance abuse testing Sampling Sample collection & stabilization devices to drive discovery and access Services Data analytics and AI, multiomic view to health & wellne
Slide 8: Innovation and Expertise in Infectious Disease Diagnostics
Innovation and Expertise in Infectious Disease Diagnostics Our technologies are the ideal platform for the emerging trends in diagnostic testing Directly suited for the current COVID-19 testing dynamic Leveraging our proven experience with HIV Self-Test and Rapid Ebola Antigen Test to develop a Coro
Slide 9: Three Distinct COVID-19 Opportunities
Three Distinct COVID-19 Opportunities Sample Collection Devices for COVID-19 Molecular Testing COVID-19 Rapid Antigen home test COVID-19 Oral Fluid Antibody ELISA Convenient, pain-free self-collection Increased access to testing Less burden on healthcare systems Minimized exposure risks to healthcar
Slide 10: All-in-one Solutions for Self-collection of Samples for Molecular COVID-19 Testing
All-in-one, easy, reliable and non-invasive self-collection of high quality DNA and RNA Ambient temperature stability Compatible with high throughput processing ORAcollect®·RNA and OMNIgene®·ORAL have received EUAs, interim authorization from Health Canada, and are CE-IVD marked Eight customers to d
Slide 11: COVID-19 Rapid Antigen Home Test
EUA submitted in Q1 2021 for Prescription home test and Professional POC test Simple, easy-to-use test to detect active COVID-19 infection anytime, anywhere with direct results available a short time later on the test stick No instrumentation or laboratory analysis needed to interpret results Based
Slide 12: COVID-19 Rapid Antigen Home Test: Three Products Covering Various Use-Cases
OraSure’s COVID-19 Rapid Antigen Home Test: Three Products Covering Various Use-Cases 2 Professional Test Rx Self-test Over-the-counter Test Rx Self-Swab Healthcare practitioner reads result Rx Self-Swab Consumer reads result OTC Self-Swab Consumer reads result Consumer Home Use via Pharmacy Rx Educ
Slide 13: SARS-CoV-2 Oral Fluid Antibody Test
No oral fluid COVID-19 antibody tests have received Emergency Use Authorization to date* Easy and non-invasive self-collection ELISA Microplate lab-based oral fluid test Short turn-around time and high-throughput Ideal for surveillance data BARDA contract to develop Data requested by FDA collected;
Slide 14: Expansion of Installed Manufacturing Capacity
Further expansion will allow 120 million total tests per year Expansion of Installed Manufacturing Capacity to Meet Anticipated Demand for COVID-19 Opportunities Current capacity for 44 million OraQuick tests per year including HIV, HCV and Ebola tests+ Installation of new lines will expand total ca
Slide 15: Trailblazer in HIV Self-Testing
Trailblazer in HIV Self-Testing First and only rapid HIV OTC test approved by FDA First and only WHO-prequalified rapid oral HIV self-test Source: WHO/UNITAID/UNAIDS Opportunities in Africa with UNITAID STAR program expansion, Europe, Eastern Europe, Central Asia and Latin America OraSure is Interna
Slide 16: Well-Positioned to Play an Important Role in the Eradication of HIV in the U.S.
Well-Positioned to Play an Important Role in the Eradication of HIV in the U.S. ENDING THE HIV EPIDEMIC: THE PLAN FOR AMERICA FY 2021 federal budget includes $386 million for EHE implementation, up from $267 million in FY 2020. Reaching the difficult to reach is key to achieving plan goals Rapid tes
Slide 17: Hepatitis C
Hepatitis C Source: WHO & CDC * VWB and FSWB only OraSure makes the first and only FDA-approved, CLIA-waived rapid HCV test* 81% of the estimated 71 million people with chronic Hepatitis C do not know their status Antiviral medications can now cure 95%+ of those infected but access to diagnosis and
Slide 18: Opportunities in Substance Abuse Testing
Opportunities in Substance Abuse Testing New federal guidelines permit oral fluid drug testing SAMHSA estimates oral fluid testing will grow to 25% of total testing by 2025 OraSure pioneered oral fluid testing for substance abuse Socially distanced, easier, less costly and more efficient sample coll
Slide 19: DNA Genotek: The Magic Behind Human Genomics
DNA Genotek: The Magic Behind Human Genomics DNA Genotek “has done for DNA collection what Google did for Web searches: made it ridiculously simple and efficient.” – TIME Magazine Illustration depicts Oragene self-collection kit
Slide 20: Microbiome Impact on Healthcare
Microbiome Impact on Healthcare
Slide 21: Services: Unmatched Offering From Sample to Answer
Services: Unmatched Offering From Sample to Answer Blue-chip customer base and technical innovation in microbiome analysis and DNA Genotek’s microbiome sampling kits Integrated lab operations in Minnesota Consolidated CoreBiome and Diversigen services under Diversigen brand Diversigen represents exp
Slide 22: Multiomics: New Health Paradigm
Multiomics: New Health Paradigm End-to-end quality in sampling, services, and bioinformatics
Slide 23: Business Development
Business Development 1 Cash and cash equivalents, short-term investments, and long-term investments as of March 31, 2020 Using robust balance sheet to create revenue and shareholder value Considering diagnostic possibilities as well as molecular $240 million in cash on balance sheet1 with no debt Fo
Slide 24: Summary
Summary Business momentum is strong Significant COVID-19 opportunity is robust part of our business for now and the foreseeable future Molecular collection devices driving significant revenue COVID-19 Antigen and Antibody tests on the road to commercialization Non-COVID business is showing resilienc